Teva Pharm / Actavis Inc. / USA Inc. / Mutual Pharmaceutical Co. / Wyeth Inc. / See PLIVA Inc. / PLIVA Inc. / Baxter Healthcare Corp. / Wyeth / /
Country
United States / /
Event
Product Issues / FDA Phase / Legal Issues / /
Facility
University of South Carolina School / OF PHARMACY / /
IndustryTerm
federal law duty / drug labeling law / drug product / state law / contrary state law / tort law / generic manufacturers / law governing design-defects / state-law claim / state law permitting / generic manufacturer / brand-name product / brand-name manufacturer / state-law duty / state design-defect law / generic drug manufacturer / federal law / generic drug manufacturers / state-law duties / state-law design-defect claims / chemical properties / little sense / healthcare providers / generic drug products / drug products / /
Harvard Law School / Food and Drug Administration / University of South Carolina School of Law / YALE / U.S. Gov’t Accountability Office / Congress / Petrie-Flom Center for Health Law Policy / Biotechnology / and Bioethics / U.S. Supreme Court / Generic Trust Fund / t Accountability Office / Court of Appeals / UN Court / US Federal Reserve / FDA / /
Person
Lydia Hill / Danielle Holley-Walker / Lewis Grossman / Jessica Kelly / Chan Mo Ahn / Colin Miller / Orrin G. Hatch / Katie Brown / Barbara Starfield / Vanessa Byars / Breyer / Stacey B. Lee / Jaime Harrison / Zoe Miller / Peter Barton Hutt / Marc T. Law / Sotomayor / I. Glenn Cohen / Inge Lewis / John E. Dicken / /
Position
pharmacist / Assistant Professor / /
Product
Fosamax / Reglan / Clinoril / Alendronate Sodium / Phenergan / metoclopramide / ANDA drug / LAW / labeling / /
ProvinceOrState
District of Columbia / South Carolina / New Hampshire / /
BOYD[removed]Do Not Delete[removed]:19 PM UNEQUAL PROTECTION UNDER THE LAW: WHY FDA SHOULD USE NEGOTIATED RULEMAKING TO REFORM